Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19537784 | 0.84 | PTGES (0.46) | KDM4EPTGESKIF11MAPTALDH1A1 | |
| SCHEMBL31682831 | 0.81 | KDM4E (0.49) | KDM4EPTGESMAPTALDH1A1GABRP | |
| SCHEMBL9132751 | 0.79 | MEN1 (0.46) | KDM4EPTGESALDH1A1MEN1KMT2A | |
| SCHEMBL31219145 | 0.76 | KDM4E (0.39) | KDM4EPTGESMAPTALDH1A1MEN1 | |
| SCHEMBL6827135 | 0.74 | METAP1 (0.55) | KDM4EPTGESMAPTALDH1A1GABRP | |
| SCHEMBL9135483 | 0.74 | BCHE (0.47) | KDM4EPTGESMAPTALDH1A1GABRA1 | |
| SCHEMBL6254106 | 0.74 | LIMK1 (0.65) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7221411 | 0.72 | LIMK1 (0.63) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8479917 | 0.72 | NPC1 (0.54) | KDM4EPTGESALDH1A1GABRPGABRD | |
| SCHEMBL6826399 | 0.71 | KDM4E (0.56) | KDM4EPTGESALDH1A1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618758-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210032266-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2021-02-04 | — | — | US | disclosed |
| US-10844075-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-11-24 | — | — | US | disclosed |
| US-10385064-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180105536-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-04-19 | — | — | US | disclosed |
| EP-2670244-B1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | UNIV HOLY GHOST DUQUESNE (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9732090-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160009731-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-01-14 | — | — | US | disclosed |
| US-9139590-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-09-22 | — | — | US | disclosed |
| US-20120264768-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2012-10-18 | — | — | US | disclosed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032266-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-11618758-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-20180105536-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-20120264768-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-10385064-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-10844075-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
| US-20160009731-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient | TK1, UACA, DSTYK | KDM4E 4436/4885PTGES 2121/4885KIF11 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.